Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 566.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.75M |
| Shares Out | 12.97M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,192 |
| Open | 44.52 |
| Previous Close | 45.16 |
| Day's Range | 41.51 - 44.88 |
| 52-Week Range | 3.26 - 158.07 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 76.50 (+82.4%) |
| Est. Earnings Date | n/a |
About GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Staffo...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GLSI stock is "Buy." The 12-month stock price forecast is 76.50, which is an increase of 82.36% from the latest price.
News
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference
Greenwich LifeSciences Set to Join Russell 2000® Index
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Set to Join Russell 2000® Index
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer ...
Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were pre...
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming th...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commerc...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
Why Greenwich LifeSciences Stock Tanked Today
The drop came despite the clinical-stage biotech announcing good news over the weekend.
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP...
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity...
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Why Greenwich LifeSciences Stock Is Rising Today
The company reported positive data for its cancer immunotherapy candidate GP2.
What's Going On With GLSI Stock And PSMT Stock Today?
Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by more than 15% after the company reported a robust immune response from its Phase 2b data supporting the GP2 clinical outcome of 0% ...
Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years F...
Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting. The company plans to publish...
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic...
STAFFORD, Texas--(BUSINESS WIRE)--GLSI Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years Follow-up
Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy
Greenwich LifeSciences is advancing cancer treatments with life-changing potential, and recent developments should boost GLSI stock's value. The post Greenwich LifeSciences Is Both a Sound Investment an...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - March 24, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduci...
Greenwich LifeSciences Could See Another Spike in Stock in Early April
On December 8, 2020, Greenwich LifeSciences (NASDAQ: GLSI) share price closed at $5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio...
Exclusive: Greenwich LifeSciences CEO Calls Stock's Meteoric Rise 'Very Emotional'
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly...
Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for C...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour - Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
Why Greenwich LifeSciences Stock Skyrocketed Today
Investors cheered an important new hire.
GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today
GLSI stock is skyrocketing again on Monday after the company appointed Dr. Jaye Thompson to run its Phase 3 clinical trials. The post GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today appeare...